ESSA Research Development vs Cost Of Revenue Analysis

EPIX Stock

USD 1.79 0.02 1.10%

ESSA Pharma financial indicator trend analysis is much more than just examining ESSA Pharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ESSA Pharma is a good investment. Please check the relationship between ESSA Pharma Research Development and its Cost Of Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.

Research Development vs Cost Of Revenue

Research Development vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ESSA Pharma Research Development account and Cost Of Revenue. At this time, the significance of the direction appears to have very strong relationship.

The correlation between ESSA Pharma's Research Development and Cost Of Revenue is 0.88. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of ESSA Pharma, assuming nothing else is changed. The correlation between historical values of ESSA Pharma's Research Development and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of ESSA Pharma are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Research Development i.e., ESSA Pharma's Research Development and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.88

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Research Development

Cost Of Revenue

Cost of Revenue is found on ESSA Pharma income statement and represents the costs associated with goods and services ESSA Pharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from ESSA Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ESSA Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.Selling General Administrative is likely to drop to about 7.5 M in 2024. Tax Provision is likely to drop to 1,368 in 2024

ESSA Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Other Liab	Net Tangible Assets	Other Assets	Long Term Debt	Net Receivables	Inventory	Property Plant Equipment	Property Plant And Equipment Net	Common Stock Shares Outstanding
Total Assets		0.59	0.37	1.0	-0.75	-0.95	0.27	0.76	0.29	0.49	0.93	0.44	0.9	-0.03	1.0	0.01	0.99	-0.29	1.0	0.82	0.59	-0.15	0.95	0.63	0.61	0.97
Other Current Liab	0.59		0.02	0.6	-0.83	-0.43	-0.08	0.81	0.21	0.39	0.38	0.62	0.4	-0.17	0.59	-0.07	0.48	-0.18	0.53	0.31	0.29	-0.05	0.41	0.56	0.69	0.46
Total Current Liabilities	0.37	0.02		0.34	-0.37	-0.43	0.72	0.4	0.54	0.18	0.43	0.57	0.28	0.72	0.37	0.26	0.37	0.16	0.35	0.36	0.58	0.15	0.31	0.58	0.45	0.31
Total Stockholder Equity	1.0	0.6	0.34		-0.75	-0.94	0.24	0.76	0.27	0.47	0.93	0.42	0.89	-0.07	1.0	0.0	0.98	-0.31	1.0	0.82	0.57	-0.15	0.95	0.62	0.6	0.98
Net Debt	-0.75	-0.83	-0.37	-0.75		0.57	-0.12	-1.0	-0.23	-0.3	-0.7	-0.63	-0.48	0.02	-0.75	0.05	-0.64	0.21	-0.7	-0.65	-0.43	0.07	-0.55	-0.76	-0.72	-0.59
Retained Earnings	-0.95	-0.43	-0.43	-0.94	0.57		-0.35	-0.6	-0.27	-0.56	-0.87	-0.37	-0.93	-0.07	-0.95	-0.04	-0.97	0.26	-0.95	-0.72	-0.67	0.18	-0.93	-0.58	-0.45	-0.97
Accounts Payable	0.27	-0.08	0.72	0.24	-0.12	-0.35		0.14	0.44	0.49	0.32	0.51	0.26	0.72	0.27	0.26	0.3	0.63	0.26	0.3	0.22	0.22	0.28	0.46	0.43	0.26
Cash	0.76	0.81	0.4	0.76	-1.0	-0.6	0.14		0.25	0.31	0.72	0.63	0.51	0.01	0.76	-0.05	0.66	-0.22	0.71	0.66	0.48	-0.08	0.57	0.78	0.72	0.61
Non Current Assets Total	0.29	0.21	0.54	0.27	-0.23	-0.27	0.44	0.25		0.36	0.26	0.44	0.27	0.52	0.29	0.67	0.28	0.12	0.25	0.34	0.35	0.2	0.35	0.12	0.62	0.23
Non Currrent Assets Other	0.49	0.39	0.18	0.47	-0.3	-0.56	0.49	0.31	0.36		0.43	0.38	0.59	0.42	0.49	0.07	0.52	0.33	0.47	0.4	0.41	-0.23	0.48	0.25	0.44	0.51
Cash And Short Term Investments	0.93	0.38	0.43	0.93	-0.7	-0.87	0.32	0.72	0.26	0.43		0.33	0.84	0.03	0.93	0.03	0.93	-0.26	0.94	0.95	0.56	-0.14	0.9	0.58	0.53	0.91
Other Current Assets	0.44	0.62	0.57	0.42	-0.63	-0.37	0.51	0.63	0.44	0.38	0.33		0.34	0.46	0.45	0.11	0.38	0.12	0.38	0.24	0.52	0.31	0.27	0.78	0.81	0.33
Other Stockholder Equity	0.9	0.4	0.28	0.89	-0.48	-0.93	0.26	0.51	0.27	0.59	0.84	0.34		0.03	0.9	0.05	0.94	-0.31	0.91	0.73	0.7	-0.25	0.9	0.47	0.41	0.95
Total Liab	-0.03	-0.17	0.72	-0.07	0.02	-0.07	0.72	0.01	0.52	0.42	0.03	0.46	0.03		-0.03	0.22	0.0	0.55	-0.06	0.03	0.42	-0.05	-0.03	0.16	0.3	-0.06
Total Current Assets	1.0	0.59	0.37	1.0	-0.75	-0.95	0.27	0.76	0.29	0.49	0.93	0.45	0.9	-0.03		0.01	0.99	-0.29	1.0	0.82	0.59	-0.15	0.95	0.63	0.61	0.97
Intangible Assets	0.01	-0.07	0.26	0.0	0.05	-0.04	0.26	-0.05	0.67	0.07	0.03	0.11	0.05	0.22	0.01		0.03	0.2	0.01	0.03	0.02	0.16	0.03	0.03	0.1	0.02
Common Stock	0.99	0.48	0.37	0.98	-0.64	-0.97	0.3	0.66	0.28	0.52	0.93	0.38	0.94	0.0	0.99	0.03		-0.28	0.99	0.81	0.61	-0.16	0.97	0.57	0.54	1.0
Other Liab	-0.29	-0.18	0.16	-0.31	0.21	0.26	0.63	-0.22	0.12	0.33	-0.26	0.12	-0.31	0.55	-0.29	0.2	-0.28		-0.31	-0.22	-0.4	0.0	-0.26	-0.07	0.09	-0.3
Net Tangible Assets	1.0	0.53	0.35	1.0	-0.7	-0.95	0.26	0.71	0.25	0.47	0.94	0.38	0.91	-0.06	1.0	0.01	0.99	-0.31		0.83	0.57	-0.15	0.96	0.59	0.55	0.99
Other Assets	0.82	0.31	0.36	0.82	-0.65	-0.72	0.3	0.66	0.34	0.4	0.95	0.24	0.73	0.03	0.82	0.03	0.81	-0.22	0.83		0.42	-0.09	0.84	0.43	0.56	0.78
Long Term Debt	0.59	0.29	0.58	0.57	-0.43	-0.67	0.22	0.48	0.35	0.41	0.56	0.52	0.7	0.42	0.59	0.02	0.61	-0.4	0.57	0.42		-0.24	0.5	0.51	0.33	0.59
Net Receivables	-0.15	-0.05	0.15	-0.15	0.07	0.18	0.22	-0.08	0.2	-0.23	-0.14	0.31	-0.25	-0.05	-0.15	0.16	-0.16	0.0	-0.15	-0.09	-0.24		-0.16	0.18	0.31	-0.18
Inventory	0.95	0.41	0.31	0.95	-0.55	-0.93	0.28	0.57	0.35	0.48	0.9	0.27	0.9	-0.03	0.95	0.03	0.97	-0.26	0.96	0.84	0.5	-0.16		0.4	0.54	0.96
Property Plant Equipment	0.63	0.56	0.58	0.62	-0.76	-0.58	0.46	0.78	0.12	0.25	0.58	0.78	0.47	0.16	0.63	0.03	0.57	-0.07	0.59	0.43	0.51	0.18	0.4		0.55	0.53
Property Plant And Equipment Net	0.61	0.69	0.45	0.6	-0.72	-0.45	0.43	0.72	0.62	0.44	0.53	0.81	0.41	0.3	0.61	0.1	0.54	0.09	0.55	0.56	0.33	0.31	0.54	0.55		0.47
Common Stock Shares Outstanding	0.97	0.46	0.31	0.98	-0.59	-0.97	0.26	0.61	0.23	0.51	0.91	0.33	0.95	-0.06	0.97	0.02	1.0	-0.3	0.99	0.78	0.59	-0.18	0.96	0.53	0.47

Click cells to compare fundamentals

ESSA Pharma Account Relationship Matchups

ESSA Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	80.6M	198.2M	169.5M	149.1M	171.5M	180.1M
Other Current Liab	24.2M	39.2M	36.4M	1.4M	1.6M	1.5M
Total Current Liabilities	1.2M	3.9M	2.3M	3.5M	4.0M	3.0M
Total Stockholder Equity	79.2M	194.0M	167.1M	145.6M	167.5M	175.8M
Net Debt	(56.3M)	(137.5M)	(56.9M)	(33.6M)	(30.3M)	(31.8M)
Retained Earnings	(81.0M)	(117.8M)	(152.9M)	(179.5M)	(161.5M)	(153.4M)
Accounts Payable	678.6K	1.4M	954.6K	2.0M	2.3M	1.4M
Cash	56.3M	137.8M	57.1M	33.7M	38.8M	34.1M
Non Current Assets Total	55.2K	567.7K	446.0K	325.3K	374.0K	383.8K
Non Currrent Assets Other	(200.7K)	277.6K	259.5K	257.2K	295.8K	181.3K
Cash And Short Term Investments	56.3M	194.9M	57.1M	148.1M	170.3M	178.8M
Other Current Assets	1.7M	2.2M	1.8M	585.4K	673.2K	1.2M
Other Stockholder Equity	31.2M	36.4M	44.0M	49.0M	56.4M	59.2M
Total Liab	1.3M	4.2M	2.4M	3.5M	4.0M	4.6M
Total Current Assets	80.6M	197.6M	169.5M	148.8M	171.1M	179.7M
Common Stock	131.1M	277.4M	278.1M	278.2M	319.9M	335.9M
Other Liab	19.6K	16.5K	127.4K	20.4K	18.3K	17.4K
Net Tangible Assets	49.0M	79.2M	194.0M	167.1M	192.2M	201.8M
Other Assets	(55.2K)	198.2M	(446.0K)	115.4M	132.7M	139.3M
Net Receivables	309.5K	489.0K	6.2K	135.1K	121.6K	115.5K
Liabilities And Stockholders Equity	80.6M	198.2M	169.5M	149.1M	171.5M	180.1M
Inventory	420.5K	(360.8K)	(309.5K)	110.6M	127.2M	133.6M
Short Term Debt	59.1K	120.7K	133.8K	80.3K	92.4K	87.8K
Common Stock Shares Outstanding	22.4M	38.5M	44.0M	44.1M	50.7M	53.2M
Non Current Liabilities Total	127K	230.6K	77K	(71.0)	(63.9)	(60.7)
Short Long Term Debt Total	59.1K	331.0K	209.8K	80.3K	72.3K	68.7K
Net Invested Capital	79.2M	194.0M	167.1M	145.6M	167.5M	103.4M
Net Working Capital	79.1M	193.7M	166.7M	145.3M	167.1M	101.6M
Capital Stock	131.1M	277.4M	278.1M	278.2M	319.9M	198.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for ESSA Stock Analysis

When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ESSA Research Development vs Cost Of Revenue Analysis

Research Development vs Cost Of Revenue

Research Development vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Research Development

Cost Of Revenue

ESSA Pharma fundamental ratios Correlations

ESSA Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ESSA Pharma fundamental ratios Accounts

Also Currently Popular

Additional Tools for ESSA Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Stockholder Equity
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Net Tangible Assets	+ 1.0	Total Current Assets

Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Common Stock	- 0.97	Retained Earnings
Net Tangible Assets	- 0.95	Retained Earnings
Total Current Assets	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Total Assets